Background:  Recently it has been found that cardiovascular disease is the most frequent cause of morbidity and mortality throughout the world. The objective of present study was to evaluate the different existing drug treatment strategies used in the management of coronary artery diseases and counsel the patients according to their modifiable risk factors and assess their quality of life.

Method: This was a prospective observational study conducted in the department of cardiology. A total of 25 patients presenting with varied category of CAD were screened and analyzed. The quality of life of patients were analyzed by Short form 36 (SF-36) Questionnaire.

Results: In this study, among 25 cases of coronary artery diseases analyzed the incidence of CAD were more common in male compared to female. Most of the patients were of the age group of 51-60 years (48%).   The prescription pattern of various cardiovascular drugs were found to be as antiplatelet drugs 25 (100%), anti-hyperlipidemic drugs 25 (100%), anti-coagulants 20 (80%), Nitrates 17(68%), potassium channel opener 13(52%), Anti- hypertensives 21 (84%)  The most commonly prescribed drug classes in coronary artery disease were antiplatelet drugs followed by anti hyperlipidemics .A total of 21 (84%) patients have improved their quality of life after the counseling.

Conclusion: The anti platelets, statins, anticoagulants and beta blockers were apparent in 90% of prescriptions which shows the rational prescribing behaviour of physicians and also in accordance with AHA/ACC guidelines.

Keywords: Coronory artery disease, Observational study, ST segment elevation MI, Non ST segment elevation MI.

1. Bandla Aswani, Purushothama Reddy, P. Yanadaiah, S. Sujatha: A study on prescribing pattern of cardiovascular drugs and potential drug-drug interactions in an inpatient cardiology unit of a cardiac care hospital at Tirupathi; European journal of pharmaceutical and medical research.
2. S M Biradar, Mohammed Naveed, P KeerthiSai, H. PruthviRaju, A Harish Kumar, Anand P Ambali, VijayaSorangavi, B Shivakumar, N V Kalyane: Journal of Drug Delivery and Therapeutics 2018; 8(6-s):89-93;http:/ / jddtonline.info.
3. Tittu George Zachariah, Subramanyan K, Pooja M, Vinayak J Kempaller :Drug utilization study in ischaemic heart disease in a tertiary care hospital, Manglore, India; International journal of basic and clinical pharmacology.
4. Elvin Zengin, Christoph Bickel, Renate B Schnabel, Tanja Zeller, Kari J Lackner, Hans J Rupprecht, Stefan Blankenberg, Dirk Westermann, Christoph Sinning for the Athero Gene – Study investigators: Risk factors of Coronary Artery Disease in Secondary Prevention- Results from the Athero Gene- study, PLoS ONE 10(7): e0131434 doi:10.1371/journal pone.0131434.
5. Sunita Dodani, Gyanendra K Sharma: Presence of coronary artery disease in diabetic and non diabetic south asian immigrants; Indian heart journal 70 (2018) 50-55.
6. Joanna M Mory’s, jerzybellwon, Stefan hofer, andrzejrynkiewicz, marcingruchala : quality of life in patients with coronary heart disease after myocardial infarction and with ischemic heart failure.
7. Anoop dinesh shah: Type 2 diabetes and incidence of cardiovascular diseases: a cohort study in 1.9 million people; Lancet diabetes endocrinal 2015:3:105-13.
8. Karolina Gierszewska, Izabela Jawoska, Michal Skrzypek, Mariusz Gasior, Robert Pudlo ; Quality of life in patients with coronary artery disease treated with coronary artery bypass grafting and hybrid coronary revascularization. Cardiology journal 2018, Vol. 25, No 5, 621-627
9. HayatoTada, Olle Mlander, Judy Z. Louie, Joeph J. Catanese, Charles M Rowland, James J Devlin, Sekar Kathiresan, Do Shiffman: Risk prediction by genetic risk scores for coronary heart disease is independent of self-reported family history, Euroean Heart Journal(2016) .
10. Dylan L Steen, Irfan khan, Laura Becker, JoAnne M Foody, KatherinaGorcyca, Robert j Sanchez, Robert P Giugliano: Patterns and predictors of lipid- lowering therapy in patients with atherosclerotic cardiovascular disease and/or diabetes mellitus in 2014: Insights from a large US managed – care population,Clinical cardiology 2016.
11. Lipid Research Clinics ProgramThe Lipid Research Clinics Primary Trial results. I. Reduction in incidence of coronary heart disease. JAMA
12. Blankenhorn DH, Azen SP, Kramsch DM, et al. Coronary angiographic changes with lovastatin therapy: the Monitored Atheros-clerosis Regression Study (MARS). Ann Intern Med1993;119:969-
13. Watts GF, Lewis B, Brunt JNH, et al. Effects on coronary artery disease of lipid-lowering diet, or diet plus cholestyramine, in the St. Thomas' Atherosclerosis Regression Study (STARS). Lancet1992;339:563-
14. Brown G, Albers JJ, Fisher LD, et al. Regression of coronaryartery disease as a result of intensive lipid-lowering therapy in men with high levels of apolipoprotein B. N Engl J Med1990;323:1289-1298ischman DL, Savage MP, Ellis S, et al. The Palmaz-Schatz stent. In: Reiber JHC, Serruys PW, eds. Advances in quantitative coronary arteriography. Vol. 137 of Developments in cardiovascular medicine. Dordrecht, the Netherlands: Kluwer Academic, 1993:553-66.
15. Fischman DL, Savage MP, Leon MB, et al. Effect of intracoronary stenting on intimal dissection after balloon angioplasty: results of quantitative and qualitative coronary analysis. J Am Coll Cardiol1991;18:1445-

Nithin Manohar R

Email: This email address is being protected from spambots. You need JavaScript enabled to view it.